The integration of artificial intelligence (AI) and machine learning (ML) models into clinical development is accelerating, promising to enhance efficiency from trial design to regulatory submission. However, the traditional 'one-size-fits-all' approach to model validation, which applies uniform, exhaustive scrutiny to all models, creates significant bottlenecks, misallocates resources, and delays innovation. This paper quantifies the cost-and-time benefits of adopting a risk-based AI model validation framework. The objective is to compare this modern, stratified approach against the inefficient baseline, focusing on late-stage clinical trials under U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) regulatory contexts. The methodology involves a comparative analysis of regulatory guidance and a risk stratification of AI models into four categories: diagnostic, prognostic, predictive, and operational. Findings indicate that a risk-based framework, supported by recent FDA and EMA guidance, aligns validation rigor with a model's potential impact on patient safety and trial integrity. High-risk models receive stringent validation, while lower-risk operational models undergo a more streamlined process, optimizing resource allocation and reducing timelines. The implications are significant: life sciences companies can accelerate the deployment of efficiency-driving AI, reduce validation-related costs, and improve regulatory compliance, thereby fostering a more agile and innovative clinical development ecosystem.
Sachin Nair (Fri,) studied this question.